Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies

Atypical hemolytic uremic syndrome (aHUS) is a rare, possibly life-threatening disease characterized by platelet activation, hemolysis and thrombotic microangiopathy (TMA) leading to renal and other end-organ damage. We originally conducted two phase 2 studies (26 weeks and 1 year) evaluating eculiz...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Kidney Int
Main Authors: Licht, Christoph, Greenbaum, Larry A, Muus, Petra, Babu, Sunil, Bedrosian, Camille L, Cohen, David J, Delmas, Yahsou, Douglas, Kenneth, Furman, Richard R, Gaber, Osama A, Goodship, Timothy, Herthelius, Maria, Hourmant, Maryvonne, Legendre, Christophe M, Remuzzi, Giuseppe, Sheerin, Neil, Trivelli, Antonella, Loirat, Chantal
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group 2015
Teme:
Clinical Trial
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4424817/
https://ncbi.nlm.nih.gov/pubmed/25651368
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/ki.2014.423
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki